Avalo Therapeutics, Inc. (NASDAQ:AVTX – Get Rating) – Equities researchers at Jefferies Financial Group lowered their Q4 2022 EPS estimates for Avalo Therapeutics in a research note issued to investors on Monday, November 14th. Jefferies Financial Group analyst C. Howerton now expects that the company will earn ($0.55) per share for the quarter, down from their previous estimate of $0.06. The consensus estimate for Avalo Therapeutics' current full-year earnings is ($2.66) per share. Jefferies Financial Group also issued estimates for Avalo Therapeutics' FY2023 earnings at ($0.54) EPS, FY2024 earnings at $0.02 EPS, FY2025 earnings at ($0.14) EPS and FY2026 earnings at ($0.10) EPS.
Get Avalo Therapeutics alerts:Separately, Oppenheimer cut their price objective on shares of Avalo Therapeutics to $10.00 in a report on Tuesday.
Avalo Therapeutics Stock Performance
AVTX opened at $5.41 on Thursday. Avalo Therapeutics has a twelve month low of $2.42 and a twelve month high of $27.36. The company has a debt-to-equity ratio of 5.23, a quick ratio of 1.07 and a current ratio of 1.07. The company has a 50-day moving average price of $4.94 and a 200 day moving average price of $5.21.Institutional Investors Weigh In On Avalo Therapeutics
Hedge funds and other institutional investors have recently modified their holdings of the company. Assenagon Asset Management S.A. purchased a new position in Avalo Therapeutics during the 3rd quarter worth $52,000. Leo Brokerage LLC purchased a new stake in Avalo Therapeutics during the first quarter worth about $45,000. Goldman Sachs Group Inc. raised its position in Avalo Therapeutics by 23.8% during the second quarter. Goldman Sachs Group Inc. now owns 649,653 shares of the company's stock worth $324,000 after acquiring an additional 124,769 shares during the last quarter. Renaissance Technologies LLC raised its position in Avalo Therapeutics by 819.1% during the first quarter. Renaissance Technologies LLC now owns 367,193 shares of the company's stock worth $266,000 after acquiring an additional 327,241 shares during the last quarter. Finally, Millennium Management LLC acquired a new position in Avalo Therapeutics during the second quarter worth about $506,000.
About Avalo Therapeutics
(Get Rating)
Avalo Therapeutics, Inc, a clinical-stage precision medicine company, discovers, develops, and commercializes targeted therapeutics for patients with unmet clinical need in immunology, immuno-oncology, and rare genetic diseases. It develops AVTX-002, a fully human anti-LIGHT monoclonal antibody, which is under Phase II clinical trial for the treatment of non-eosinophilic asthma, as well as inflammatory bowel disease, including moderate to severe Crohn's disease, and ulcerative colitis; and Phase III clinical trial for the treatment of COVID-19 acute respiratory distress syndrome.
Read More
- Get a free copy of the StockNews.com research report on Avalo Therapeutics (AVTX)
- Does ASML's November Rally Have Staying Power?
- Verra Mobility Stock Has Returned Back to the Station
- Is Advance Auto Parts a Buy After its Earnings Crash?
- BJ's Wholesale Club: Beware The Sell-Side
- The Next Catalyst For Mullen Automotive Stock Is December 23rd
Receive News & Ratings for Avalo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avalo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.